Stability studies of rifampicin in plasma and urine of tuberculosis patients according to the European Medicines Agency Guidelines
Stability studies of rifampicin in plasma and urine of tuberculosis patients according to the European Medicines Agency Guidelines
复制标题
DOI：
10.4155/bio-2018-0174
复制
发表时间：
2019-04-01
期刊：
影响因子：
1.8
通讯作者：
Jain, Abhishek
中科院分区：
文献类型：
--
作者：
Mishra, Pooja;Pawar, Rajendra-Prasad;Jain, Abhishek
目的：大环内酯类抗生素利福平用于治疗几种感染，如肺结核。这种药物会腐烂成利福平的醌。结果/方法：将生物液在胶束溶液中稀释后直接进样。采用C18色谱柱，流动相为0.15M十二烷基硫酸钠-6%1-戊醇磷酸盐-缓冲液(pH=7)，运行速度为1ml/min，在不到15分钟的时间内完成分析。检测波长为337 nm。方法通过欧洲药品管理局的指南进行验证。还研究了利福平分解为利福平醌的反应。讨论/结论：该方法快速、易操作、经济、环保，样品吞吐量高。该方法已成功应用于结核病患者血浆和尿液中利福平的监测。
Aim: The macrolide antibiotic rifampicin is prescribed against several infections, like tuberculosis disease. This drug decays to rifampicin quinone. Results/methodology: The biological fluids were diluted in a micellar solution and directly injected. Using a C18 column and a mobile phase of 0.15 M SDS-6% 1-pentanol phosphate-buffered at pH 7, running at 1 ml/min, the analytes were resolved in less than 15 min. The detection was by absorbance at 337 nm. Method was validated by the guidelines of the European Medicines Agency. Decomposition of rifampicin to rifampicin quinone was also studied. Discussion/conclusion: Procedure is rapid, easy-to-handle, economic, eco-friendly and with a high sample throughput. It was successfully used to monitor rifampicin in the plasma and urine of tubercular patients.